PATENT CLAIM ANALYSIS

Application Number: 15778207
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "254050"]

Abstract:
Provided herein are triazole compounds and pharmaceutical compositions comprising said compounds useful as modulators of DAGL(α) and DAGL(β). In some embodiments, the compounds described herein are selective DAGL(α) inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of neurodegenerative or neuroinflammatory disease.

Claim (Index 55):
A compound having the structure: or a solvate, hydrate, N-oxide, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 93.0
- Lexical Diversity: 1.63889
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14886332', '15533978', '15986747', '15440396', '13594223']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7655478825988745
- 35 USC 102 Novelty (BERT): 0.5478390503792021
- Combined Prediction Score: 0.7437769993769072
- Mean Citation Score: 382.15839
- Max Citation Score: 386.30502
- Similarity Product: 317.2854489972568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test